FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Dermatologic and Ophthalmic Drugs Advisory Committee Meeting

FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH ADVISORY COMMITTEE CONFERENCE ROOM

MAY 29, 2008

AGENDA

The committee will discuss new drug application (NDA) 22-212, difluprednate ophthalmic emulsion, Sirion Therapeutics, Inc., proposed for the treatment of inflammation and pain following ocular surgery.

8:00 a.m.	Call to Order and Opening Remarks	Marijean Miller, M.D. Acting Chair, Dermatologic and Ophthalmic Drugs Advisory Committee
	Introduction of Committee	
	Conflict of Interest Statement	Yvette Waples, Pharm.D. Designated Federal Official
8:15 a.m.	FDA Introductory Remarks	Wiley Chambers, M.D. Acting Director, Division of Anti-Infective and Ophthalmic Products, CDER, FDA
INDUSTRY PR	ESENTATION	Ophulanine Hoddels, CDER, FDA
8:20 a.m.	Difluprednate: Efficacy and Safety Review	Roger Vogel, M.D. Senior Vice President and Chief Medical Officer, Sirion Therapeutics
9: 05 a.m.	Questions/Clarifications	
9: 20 a.m.	BREAK	
FDA PRESENT	FATION	
9: 35 a.m.	Division of Anti-Infective and Ophthalmology Products Advisory Committee Meeting for NDA 21-212 Difluprednate	Sonal Wadhwa, M.D. Clinical Reviewer, Division of Anti-Infective and Ophthalmic Products, CDER, FDA
10: 20 a.m.	Questions/Clarifications	
10: 35 a.m.	BREAK	
11: 00 a.m.	OPEN PUBLIC HEARING	

12: 00 a.m.

1:00 p.m.

Panel Discussion/Questions

ADJOURNMENT